mcleanap

About mcleanap

This author has not yet filled in any details.
So far mcleanap has created 19 blog entries.

ADVANCED PROTEOME THERAPEUTICS CORPORATION ANNOUNCES THE APPOINTMENT OF DR. RANDAL CHASE TO ITS EXECUTIVE LEADERSHIP TEAM AND THE GRANT OF STOCK OPTIONS

2017-04-08T20:59:12+00:00

Vancouver, British Columbia, February 6, 2017 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its executive leadership team to help shape the Company’s future and advance its technology and business objectives in the domain of antibody-based therapeutics. Effective [...]

ADVANCED PROTEOME CLOSES THIRD TRANCHE OF PRIVATE PLACEMENT

2017-04-08T20:43:27+00:00

VANCOUVER, BC – January 25, 2017 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has closed the third tranche of a non-brokered private placement (the “Private Placement”) announced October 25, 2016 by the issuance of 252,000 units (“Units”) at a purchase price of [...]

ADVANCED PROTEOME GRANTS STOCK OPTIONS

2017-04-08T20:44:50+00:00

VANCOUVER, BC – January 23, 2017 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) announces the grant of incentive stock options to directors, officers, employees and consultants to purchase an aggregate of 1,005,000 common shares in the capital of the Company, exercisable at a price of CDN $0.05 per [...]

ADVANCED PROTEOME THERAPEUTICS CORPORATION ANNOUNCES ISSUANCE OF U.S. PATENT COVERING NOVEL MOLECULES FOR THE TREATMENT OF CANCER

2017-04-09T23:53:02+00:00

Vancouver, British Columbia, January 17, 2017 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce issuance of APC’s U.S. Patent Application 14/400,190 titled “Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”. The patent covers multiple examples of novel molecular entities, linked proteins, [...]

APC FILES INTELLECTUAL PROPERTY COVERING METHODS OF ANTIBODY MODIFICATIONS BEARING ON THE DISCOVERY AND DEVELOPMENT OF CANCER THERAPEUTICS

2017-04-09T23:52:45+00:00

Vancouver, British Columbia, January 9, 2017 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has filed intellectual property to cover methods for site-selective labeling of antibodies and related composition of matter that possess potential commercial value, particularly in the field of medicine and [...]

ADVANCED PROTEOME ANNOUNCES CLOSING OF SECOND TRANCHE OF APC PRIVATE PLACEMENT, EXTENSION OF THIRD TRANCHE AND CLOSING OF SUBSIDIARY PRIVATE PLACEMENT

2017-04-09T23:54:42+00:00

VANCOUVER, BC – December 23, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has closed the second tranche of a non-brokered private placement (the “APC Private Placement”) announced October 25, 2016 to raise an aggregate of $600,000 through the issuance of (i) [...]

ADVANCED PROTEOME THERAPEUTICS CORPORATION ANNOUNCES NOTICE OF ALLOWANCE FOR KEY U.S. PATENT COVERING LINKAGE OF TWO OR MORE PROTEINS FOR THE TREATMENT OF CANCER

2017-04-20T20:45:51+00:00

Vancouver, British Columbia, December 19, 2016 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for APC’s U.S. Patent Application Serial Number 14/400,190 titled “Site-Specific Labeling and Targeted Delivery of Proteins [...]

APC INVENTS QUANTITATIVE METHOD FOR ASSESSING PATTERN OF ANTIBODY LABELING IMPACTING THE EMERGING, RAPIDLY GROWING MARKET FOR ANTIBODY-DRUG CONJUGATES (ADC)

2017-04-20T20:45:23+00:00

Vancouver, British Columbia, November 29, 2016 (Marketwired) – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according [...]

ADVANCED PROTEOME EXTENDS CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

2017-04-20T20:47:05+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia – November 24, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) announces that it has requested and received TSX Venture Exchange approval to extend closing of the second tranche of [...]

ADVANCED PROTEOME ANNOUNCES PRIVATE PLACEMENT OF SUBSIDIARY

2017-04-20T20:49:10+00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia – November 17, 2016 - Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8)) announces a non-brokered private placement of its wholly-owned subsidiary 1090573 B.C. Ltd. (“PrivCo”) of up to 6,000,000 units (the [...]